Panacea Biotec Ltd
NSE:PANACEABIO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Panacea Biotec Ltd
Income from Continuing Operations
Panacea Biotec Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Panacea Biotec Ltd
NSE:PANACEABIO
|
Income from Continuing Operations
-₹81.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
|
Transgene Biotek Ltd
BSE:526139
|
Income from Continuing Operations
-₹19.1m
|
CAGR 3-Years
35%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
Z
|
Zenotech Laboratories Ltd
BSE:532039
|
Income from Continuing Operations
₹33.6m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Hester Biosciences Ltd
NSE:HESTERBIO
|
Income from Continuing Operations
₹424.8m
|
CAGR 3-Years
11%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Biocon Ltd
NSE:BIOCON
|
Income from Continuing Operations
₹6.3B
|
CAGR 3-Years
7%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
3%
|
|
Panacea Biotec Ltd
Glance View
Panacea Biotec Ltd. is a biotechnology company, which is engaged in the business of research, development, manufacture, and marketing of vaccines and pharmaceutical formulations. The company is headquartered in New Delhi, Delhi. The Company’s research areas include new chemical entities (NCE), new biological entities (NBE) novel drug delivery system (NDDS) based pharmaceutical formulations, novel peptides and human monoclonal antibodies and vaccine development. The Company’s product portfolio includes pain management, diabetes & cardiovascular management, oncology, renal disease management, osteoporosis management, anti-tubercular, gastrointestinal care products and vaccines. The Company’s subsidiaries include Panacea Biotec Pharma Limited, Panacea Biotec (International) SA, PanEra Biotec Private Limited and Meyten Realtech Private Limited.
See Also
What is Panacea Biotec Ltd's Income from Continuing Operations?
Income from Continuing Operations
-81.5m
INR
Based on the financial report for Dec 31, 2025, Panacea Biotec Ltd's Income from Continuing Operations amounts to -81.5m INR.
What is Panacea Biotec Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
45%
Over the last year, the Income from Continuing Operations growth was 7%.
